First International Patient Begins Innovative CAR-T Therapy for Solid Tumors in Shanghai

In a groundbreaking milestone for global oncology, the Jiahui International Cancer Center in Shanghai has welcomed its first international patient undergoing treatment with Satri-cel, the world’s first CAR-T cell therapy approved for solid tumors. This event underscores the growing prominence of China in advancing cancer treatment options and broadening access to innovative therapies.

Josh, a 59-year-old patient from New Zealand battling advanced gastroduodenal cancer, traveled to Shanghai after facing increasingly limited therapeutic options in his home country. Following biomarker testing that confirmed his eligibility for Satri-cel, he became part of this significant medical advancement.

The approval of Satri-cel by Chinese authorities represents a remarkable shift in the realm of cellular immunotherapy, showcasing its potential to revolutionize treatment protocols for solid tumors. As the demand for innovative cancer treatments grows globally, the Jiahui International Cancer Center is poised to play a pivotal role in facilitating patient access to these groundbreaking solutions.

After completing a thorough multidisciplinary evaluation and establishing a treatment plan at the Jiahui Center, Josh successfully underwent leukapheresis, a procedure essential for the manufacturing of his CAR-T cells. This treatment is currently only available within China, highlighting the center's unique position in providing access to cutting-edge oncological innovations. The reintroduction of his engineered CAR-T cells is slated for the coming weeks, propelling Josh's journey towards potential recovery.

Doctor Linli Xuan, head of medical oncology at the Jiahui Center, expressed the significance of this historic milestone, stating, "The market authorization of Satri-cel marks a historic milestone not only for advanced gastric cancer patients but also for the future of oncology worldwide. We are honored that the first international patient chose the Jiahui International Cancer Center for this revolutionary treatment."

The Jiahui International Cancer Center has established itself as a leading facility in China, providing comprehensive oncology services that span medical oncology, surgical oncology, radiation oncology, precision medicine, and advanced cellular therapies. Its multidisciplinary approach, combined with a dedicated focus on international patients, enables the center to offer tailored solutions, including medical record analysis, consultations with specialists, multilingual coordination, treatment planning, logistical assistance, and ongoing follow-up care.

As interest in Chinese medical innovations continues to rise around the world, Jiahui remains committed to ensuring that international patients have access to state-of-the-art treatments coupled with personalized support throughout their healthcare journey. Amidst these developments, Jiahui stands as a beacon of hope for patients worldwide seeking advanced oncology solutions in a continuously evolving landscape.

For more information on the Jiahui Center and this extraordinary milestone, read the full article at jiahui.com/en/news/216. The center is dedicated to transforming cancer care through innovation and global collaboration, allowing patients from different backgrounds to benefit from the latest advancements in cancer therapy.